Efficacy of Immune Checkpoint Inhibitors Combinations as First-Line Systemic Treatment in Patients with Advanced Urothelial Carcinoma: A Systematic Review and …
FSM Monteiro, A Soares, V Mollica, CA Leite… - Critical Reviews in …, 2024 - Elsevier
Background Combinations of immune checkpoint inhibitors (ICI) with platinum-based
chemotherapy (PlatinumCT) or with another ICI in the first-line setting for patients with …
chemotherapy (PlatinumCT) or with another ICI in the first-line setting for patients with …
Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and …
E Germanà, L Pepe, C Pizzimenti, M Ballato… - International Journal of …, 2024 - mdpi.com
The management of advanced bladder carcinoma involves a multidisciplinary approach, but
the prognosis remains poor for many patients. The immune system plays a crucial role in this …
the prognosis remains poor for many patients. The immune system plays a crucial role in this …
Platinum-based chemotherapy induces opposing effects on immunotherapy response-related spatial and stromal biomarkers in the bladder cancer microenvironment
MA Chelushkin, J van Dorp, S van Wilpe… - Clinical Cancer …, 2024 - aacrjournals.org
Purpose: Platinum-based chemotherapy and immune checkpoint inhibitors are key
components of systemic treatment for muscle-invasive and advanced urothelial cancer. The …
components of systemic treatment for muscle-invasive and advanced urothelial cancer. The …
How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma
M Larroquette, F Lefort, C Domblides, L Héraudet… - Cancers, 2024 - mdpi.com
Simple Summary Metastatic bladder carcinoma is a cancer with a poor prognosis, for which
treatments have remained the same for several decades. Immunotherapy has revolutionized …
treatments have remained the same for several decades. Immunotherapy has revolutionized …
A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy?
L Gasperoni, L Del Bono, A Ossato, EF Giunta… - Cancers, 2024 - mdpi.com
Simple Summary Recently, numerous treatments have been approved for patients with
previously untreated locally advanced or metastatic urothelial cancer. These combinations …
previously untreated locally advanced or metastatic urothelial cancer. These combinations …
Immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced urothelial cancer: an updated systematic review and meta-analysis …
I Mamede, L Escalante-Romero, DSG Celso… - Clinical Genitourinary …, 2024 - Elsevier
Introduction Platinum-based chemotherapy (CTX) has historically been the primary
treatment for advanced urothelial cancer (aUC), with limited alternative options. The …
treatment for advanced urothelial cancer (aUC), with limited alternative options. The …
Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic …
M Miyake, N Nishimura, Y Oda, T Miyamoto… - International Journal of …, 2024 - Springer
Background Maintenance avelumab is currently recommended for patients with
unresectable and/or metastatic (mUC) achieving at least stable disease (SD) on first-line …
unresectable and/or metastatic (mUC) achieving at least stable disease (SD) on first-line …
[HTML][HTML] Combination therapies targeting different aspects of tumor biology for patients with advanced urothelial carcinoma
M Miyake - Translational Andrology and Urology, 2024 - ncbi.nlm.nih.gov
Urothelial carcinoma (UC) originates from the urothelial lining renal pelvis, ureter, bladder,
and urethra. Based on the report from Global Cancer Statistics 2020, bladder cancer is the …
and urethra. Based on the report from Global Cancer Statistics 2020, bladder cancer is the …
Evolution of front-line immunotherapy for metastatic urothelial cancer
AO Siefker-Radtke, M Desai - The Lancet Oncology, 2024 - thelancet.com
In The Lancet Oncology, Enrique Grande and colleagues1 and Aristotelis Bamias and
colleagues2 report the final results of IMvigor 130, a clinical trial exploring the role for …
colleagues2 report the final results of IMvigor 130, a clinical trial exploring the role for …
Behandlung uroonkologischer Patienten
I Bußhoff, A Hübner, M Vermeulen, M Wallisch… - Die Onkologie, 2024 - Springer
Zusammenfassung Die Behandlung uroonkologischer Erkrankungen wird immer
individueller und dadurch auch komplexer. Aktuelle Erkenntnisse zur Systemtherapie von …
individueller und dadurch auch komplexer. Aktuelle Erkenntnisse zur Systemtherapie von …